Skip Navigation



European Heart Journal Advance Access published online on March 21, 2007
European Heart Journal, doi:10.1093/eurheartj/ehm032
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/9/1085    most recent
ehm032v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Riksen, N. P.
Right arrow Articles by Rongen, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Riksen, N. P.
Right arrow Articles by Rongen, G. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Augmented hyperaemia and reduced tissue injury in response to ischaemia in subjects with the 34C > T variant of the AMPD1 gene

Niels P. Riksen1,2,*, Barbara Franke3, Wim J.G. Oyen4, George F. Borm5, Petra van den Broek1, Otto C. Boerman4, Paul Smits1,2 and Gerard A. Rongen1,2

1 Department of Pharmacology–Toxicology, Radboud University Nijmegen Medical Centre, Geert Grooteplein 21, 6525 EZ, PO Box 9101, 6500 HB Nijmegen, The Netherlands
2 Department of Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
3 Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
4 Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
5 Department of Epidemiology and Biostatistics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Received 1 October 2006; revised 31 January 2007; accepted 23 February 2007.

* Corresponding author. Tel: +31 24 3613691; fax: +31 24 3614214. E-mail address: n.riksen{at}aig.umcn.nl

Aims: In patients with coronary artery disease, the 34C > T variant of the adenosine mono-phosphate deaminase gene (AMPD1), encoding a dysfunctional protein, predicts improved survival. We hypothesized that in subjects with this variant allele, ischaemia-induced intracellular adenosine formation is increased, augmenting reactive hyperaemia and ischaemic tolerance.

Methods and results: We selected 10 healthy subjects with the CT genotype and 10 CC controls. The forearm vasodilator response to 2 and 5 min of ischaemia (venous occlusion plethysmography, expressed as percentage of maximum blood flow after 13 min of ischaemia) was higher in the CT group 56% (49–74%) and 77% (71–86%) vs. 49% (42–53%) and 60% (55–70%) in the CC group [median (interquartile range), P = 0.01]. Additionally, ischaemia–reperfusion injury was assessed in the thenar muscle using 99mTc-annexin A5 scintigraphy after forearm ischaemic exercise to detect externalized membrane phosphatidylserines. At reperfusion, 99mTc-annexin was administered intravenously. The change in annexin targeting between 1 and 4 h post-injection was –2.3% (interquartile range –2.4 to –1.6%) in the CT group vs. –0.3% (–0.6 to 1.3%) in controls (n = 7 in both groups, P = 0.03).

Conclusion: The 34C > T variant of AMPD1 augments vasodilation and reduces tissue injury in response to forearm ischaemia. These mechanisms could contribute to the survival benefit of cardiovascular patients with this variant allele.

Key Words: Adenosine • AMPD1 genotype • Ischaemia • Blood flow • Scintigraphy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.